Spots Global Cancer Trial Database for Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment

Official Title: Sportivumab - Feasibility of Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment

Study ID: NCT03171064

Conditions

PD-1 Antibodies

Exercise

Melanoma

Interventions

Resistance and Endurance Exercise

Study Description

Brief Summary: Checkpoint inhibitors like the PD-1 antibodies Pembrolizumab and Nivolumab represent standard of care for patients with metastasized melanoma. Numerous high quality studies demonstrate that endurance and resistance training in cancer patients is safe and elicits beneficial effects. However, there is no systematic experience with regard to exercise interventions in patients undergoing checkpoint inhibitor treatment. Therefore, the Sportivumab Study aimed to investigate safety, feasibility and effectivity of a 12 week combined resistance and endurance exercise intervention program during checkpoint inhibitor treatment. It is planned to enroll 40 patients. Participants will be randomized into an experimental and a wait-list control group (20 per group). The wait-list control group will receive the exercise intervention program after week 13 of enrollment.

Detailed Description: